Clinical Trial: A Safety and Efficacy Follow-up Study With Levetiracetam in Children (4-17 Years Old) Suffering From Absence Seizures

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A 30-month Safety and Efficacy Follow-up Study With Levetiracetam at Individualized Optimal Dose in Children (4-17 Years Old at Inclusion) Suffering From Typical Absences

Brief Summary: This long-term open label follow-up trial gave pediatric subjects suffering from typical absences in CAE or JAE the opportunity to continue levetiracetam treatment after participation in the pilot study (study N162) or the double-blind study (study N163). Safety and efficacy data were obtained.

Detailed Summary:
Sponsor: UCB Pharma

Current Primary Outcome: Continue levetiracetam treatment after participation in the pilot-study N162 or in study N163; Assess long-term safety profile and efficacy of levetiracetam

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: UCB Pharma

Dates:
Date Received: October 15, 2007
Date Started: May 2000
Date Completion:
Last Updated: September 16, 2013
Last Verified: September 2009